395 related articles for article (PubMed ID: 29069777)
1. Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells.
Skalniak L; Zak KM; Guzik K; Magiera K; Musielak B; Pachota M; Szelazek B; Kocik J; Grudnik P; Tomala M; Krzanik S; Pyrc K; Dömling A; Dubin G; Holak TA
Oncotarget; 2017 Sep; 8(42):72167-72181. PubMed ID: 29069777
[TBL] [Abstract][Full Text] [Related]
2. Immune Checkpoint Blockade Mediated by a Small-Molecule Nanoinhibitor Targeting the PD-1/PD-L1 Pathway Synergizes with Photodynamic Therapy to Elicit Antitumor Immunity and Antimetastatic Effects on Breast Cancer.
Zhang R; Zhu Z; Lv H; Li F; Sun S; Li J; Lee CS
Small; 2019 Dec; 15(49):e1903881. PubMed ID: 31702880
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse.
Ashizawa T; Iizuka A; Tanaka E; Kondou R; Miyata H; Maeda C; Sugino T; Yamaguchi K; Ando T; Ishikawa Y; Ito M; Akiyama Y
Biomed Res; 2019; 40(6):243-250. PubMed ID: 31839668
[TBL] [Abstract][Full Text] [Related]
4. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1).
Zak KM; Grudnik P; Guzik K; Zieba BJ; Musielak B; Dömling A; Dubin G; Holak TA
Oncotarget; 2016 May; 7(21):30323-35. PubMed ID: 27083005
[TBL] [Abstract][Full Text] [Related]
5. Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1.
Guzik K; Zak KM; Grudnik P; Magiera K; Musielak B; Törner R; Skalniak L; Dömling A; Dubin G; Holak TA
J Med Chem; 2017 Jul; 60(13):5857-5867. PubMed ID: 28613862
[TBL] [Abstract][Full Text] [Related]
6. Approaching the Dimerization Mechanism of Small Molecule Inhibitors Targeting PD-L1 with Molecular Simulation.
Liang J; Wang B; Yang Y; Liu B; Jin Y
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674800
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive in vitro characterization of PD-L1 small molecule inhibitors.
Ganesan A; Ahmed M; Okoye I; Arutyunova E; Babu D; Turnbull WL; Kundu JK; Shields J; Agopsowicz KC; Xu L; Tabana Y; Srivastava N; Zhang G; Moon TC; Belovodskiy A; Hena M; Kandadai AS; Hosseini SN; Hitt M; Walker J; Smylie M; West FG; Siraki AG; Lemieux MJ; Elahi S; Nieman JA; Tyrrell DL; Houghton M; Barakat K
Sci Rep; 2019 Aug; 9(1):12392. PubMed ID: 31455818
[TBL] [Abstract][Full Text] [Related]
8. Preparation of Biphenyl-Conjugated Bromotyrosine for Inhibition of PD-1/PD-L1 Immune Checkpoint Interactions.
Kim EH; Kawamoto M; Dharmatti R; Kobatake E; Ito Y; Miyatake H
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32455628
[TBL] [Abstract][Full Text] [Related]
9. Raloxifene, a SERM targets PD-L1: an in-silico study.
Chopra C; Yodun T; Singh H; Singh B; Singh SK; Goutam U
Am J Transl Res; 2023; 15(8):5206-5215. PubMed ID: 37692949
[TBL] [Abstract][Full Text] [Related]
10. Flurbiprofen as a biphenyl scaffold for the design of small molecules binding to PD-L1 protein dimer.
Bailly C; Vergoten G
Biochem Pharmacol; 2020 Aug; 178():114042. PubMed ID: 32445869
[TBL] [Abstract][Full Text] [Related]
11. Small-molecule PD-L1 inhibitor BMS1166 abrogates the function of PD-L1 by blocking its ER export.
Chen FF; Li Z; Ma D; Yu Q
Oncoimmunology; 2020 Oct; 9(1):1831153. PubMed ID: 33110706
[TBL] [Abstract][Full Text] [Related]
12. Further investigation of blockade effects and binding affinities of selected natural compounds to immune checkpoint PD-1/PD-L1.
Li H; Seeram NP; Liu C; Ma H
Front Oncol; 2022; 12():995461. PubMed ID: 36172167
[TBL] [Abstract][Full Text] [Related]
13. Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis.
Black M; Barsoum IB; Truesdell P; Cotechini T; Macdonald-Goodfellow SK; Petroff M; Siemens DR; Koti M; Craig AW; Graham CH
Oncotarget; 2016 Mar; 7(9):10557-67. PubMed ID: 26859684
[TBL] [Abstract][Full Text] [Related]
14. Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB.
Gowrishankar K; Gunatilake D; Gallagher SJ; Tiffen J; Rizos H; Hersey P
PLoS One; 2015; 10(4):e0123410. PubMed ID: 25844720
[TBL] [Abstract][Full Text] [Related]
15. Partial Least-Squares Discriminant Analysis and Ensemble-Based Flexible Docking of PD-1/PD-L1 Inhibitors: A Pilot Study.
Kuang Z; Heng Y; Huang S; Shi T; Chen L; Xu L; Mei H
ACS Omega; 2020 Oct; 5(41):26914-26923. PubMed ID: 33111018
[TBL] [Abstract][Full Text] [Related]
16. Stapled peptide PROTAC induced significantly greater anti-PD-L1 effects than inhibitor in human cervical cancer cells.
Shi YY; Wang AJ; Liu XL; Dai MY; Cai HB
Front Immunol; 2023; 14():1193222. PubMed ID: 37325638
[TBL] [Abstract][Full Text] [Related]
17. Progress in small-molecule inhibitors targeting PD-L1.
Xu J; Kong Y; Zhu P; Du M; Liang X; Tong Y; Li X; Dong C
RSC Med Chem; 2024 Apr; 15(4):1161-1175. PubMed ID: 38665838
[TBL] [Abstract][Full Text] [Related]
18. Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer.
Czink E; Kloor M; Goeppert B; Fröhling S; Uhrig S; Weber TF; Meinel J; Sutter C; Weiss KH; Schirmacher P; Doeberitz MVK; Jäger D; Springfeld C
Cold Spring Harb Mol Case Stud; 2017 Sep; 3(5):. PubMed ID: 28619747
[TBL] [Abstract][Full Text] [Related]
19. An updated patent review on PD-1/PD-L1 antagonists (2022-present).
Uzar W; Kaminska B; Rybka H; Skalniak L; Magiera-Mularz K; Kitel R
Expert Opin Ther Pat; 2024 Jun; ():1-24. PubMed ID: 38903044
[TBL] [Abstract][Full Text] [Related]
20. Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.
Dong ZY; Wu SP; Liao RQ; Huang SM; Wu YL
Tumour Biol; 2016 Apr; 37(4):4251-61. PubMed ID: 26779629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
